{"id":256,"date":"2020-09-08T16:22:06","date_gmt":"2020-09-08T20:22:06","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=256"},"modified":"2020-09-08T16:22:06","modified_gmt":"2020-09-08T20:22:06","slug":"fdas-new-mapp-shows-the-route-to-changing-ownership-of-generic-drug-applications","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/09\/08\/fdas-new-mapp-shows-the-route-to-changing-ownership-of-generic-drug-applications\/","title":{"rendered":"FDA&#8217;s New MAPP Shows the Route to Changing Ownership of Generic Drug Applications"},"content":{"rendered":"<p>The U.S. Food &amp; Drug Administration (FDA) recently issued a new Manual of Policies and Procedures (MAPP), in which it explains the Office of Generic Drugs\u2019 (OGD) policy on facilitating changes to generic drug applications and updating the Orange Book to reflect those changes.<\/p>\n<p><a title=\"FDA Manual of Policies and Procedures\" href=\"https:\/\/www.fda.gov\/media\/141551\/download\" target=\"_blank\" rel=\"noopener noreferrer\">MAPP 5242.1<\/a>\u00a0makes clear that the policies, processes and procedures for changing ownership of an application differ based on whether the change is effected by a simple transfer of ownership or whether it results from a corporate merger or acquisition.<\/p>\n<p>To read the full text of this Duane Morris\u00a0<em>Alert<\/em>, please\u00a0<a href=\"https:\/\/www.duanemorris.com\/alerts\/new_mapp_explains_process_changing_ownership_generic_drug_applications_0920.html#\">visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food &amp; Drug Administration (FDA) recently issued a new Manual of Policies and Procedures (MAPP), in which it explains the Office of Generic Drugs\u2019 (OGD) policy on facilitating changes to generic drug applications and updating the Orange Book to reflect those changes. MAPP 5242.1\u00a0makes clear that the policies, processes and procedures for changing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/09\/08\/fdas-new-mapp-shows-the-route-to-changing-ownership-of-generic-drug-applications\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA&#8217;s New MAPP Shows the Route to Changing Ownership of Generic Drug Applications&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[29,329,123,388,321,498,497,96,298,119],"ppma_author":[521],"class_list":["post-256","post","type-post","status-publish","format-standard","hentry","category-general","tag-fda","tag-generic-drugs","tag-generics","tag-justin-stern","tag-mapp","tag-office-of-generic-drugs","tag-ogd","tag-orange-book","tag-patrick-gallagher","tag-rick-ball"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","author_category":"1","last_name":"Sullivan","first_name":"Margaret","job_title":"","user_url":"http:\/\/www.duanemorris.com","description":"<a href=\"http:\/\/www.duanemorris.com\">Visit the Duane Morris website.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=256"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/256\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=256"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}